{"transactions":[{"id":737016,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-06-16T12:28:00.000Z","date":"2026-06-11","kind":"sale","planned":true,"acquired":false,"shares":106563,"price":34.0954,"value":3633308.1102,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.985 to $34.25, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":65621,"source":{"system":"sec-edgar","filing":"0001193125-26-271862","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526271862/ownership.xml","form_type":"4"}},{"id":776051,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-05-18T20:00:48.000Z","date":"2026-05-14","kind":"sale","planned":true,"acquired":false,"shares":153251,"price":35.6107,"value":5457375.3857,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.59 to $35.80, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":172184,"source":{"system":"sec-edgar","filing":"0001193125-26-228870","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526228870/ownership.xml","form_type":"4"}},{"id":854929,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-09T20:22:06.000Z","date":"2026-03-05","kind":"exercise","planned":false,"acquired":false,"shares":19916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on March 5, 2025, with 19,916 vested on March 5, 2026, and 19,916 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on March 5, 2025, with 19,916 vested on March 5, 2026, and 19,916 vesting on each of March 5, 2027, March 5, 2028 and March 5, 2029."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":59748,"derivative":{"underlying":"Ordinary Shares","underlying_shares":19916},"source":{"system":"sec-edgar","filing":"0001193125-26-098573","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526098573/ownership.xml","form_type":"4"}},{"id":854928,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-09T20:22:06.000Z","date":"2026-03-05","kind":"exercise","planned":false,"acquired":true,"shares":19916,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":325435,"source":{"system":"sec-edgar","filing":"0001193125-26-098573","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526098573/ownership.xml","form_type":"4"}},{"id":857145,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-06T21:08:29.000Z","date":"2026-03-04","kind":"grant","planned":false,"acquired":true,"shares":53175,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted share units were granted on March 4, 2026, with 13,293 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 13,296 vesting on March 4, 2030."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted share units were granted on March 4, 2026, with 13,293 vesting on each of March 4, 2027, March 4, 2028 and March 4, 2029, and 13,296 vesting on March 4, 2030."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":53175,"derivative":{"underlying":"Ordinary Shares","underlying_shares":53175},"source":{"system":"sec-edgar","filing":"0001193125-26-096513","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526096513/ownership.xml","form_type":"4"}},{"id":857144,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-06T21:08:29.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":false,"shares":23251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were granted on March 4, 2024, with 23,251 vested on each of March 4, 2025 and March 4, 2026, 23,251 vesting on March 4, 2027, and 23,253 vesting on March 4, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were granted on March 4, 2024, with 23,251 vested on each of March 4, 2025 and March 4, 2026, 23,251 vesting on March 4, 2027, and 23,253 vesting on March 4, 2028."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":46503,"derivative":{"underlying":"Ordinary Shares","underlying_shares":23251},"source":{"system":"sec-edgar","filing":"0001193125-26-096513","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526096513/ownership.xml","form_type":"4"}},{"id":857143,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-06T21:08:29.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":false,"shares":33512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":33512},"source":{"system":"sec-edgar","filing":"0001193125-26-096513","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526096513/ownership.xml","form_type":"4"}},{"id":857142,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-06T21:08:29.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":true,"shares":23251,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":305519,"source":{"system":"sec-edgar","filing":"0001193125-26-096513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526096513/ownership.xml","form_type":"4"}},{"id":857141,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-06T21:08:29.000Z","date":"2026-03-04","kind":"exercise","planned":false,"acquired":true,"shares":33512,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":282268,"source":{"system":"sec-edgar","filing":"0001193125-26-096513","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526096513/ownership.xml","form_type":"4"}},{"id":859908,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-05T21:03:19.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":141478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":141478},"source":{"system":"sec-edgar","filing":"0001193125-26-093903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526093903/ownership.xml","form_type":"4"}},{"id":859907,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2026-03-05T21:03:19.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":false,"shares":49800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024, March 3, 2025 and March 4, 2026, and 49,802 vesting on March 3, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024, March 3, 2025 and March 4, 2026, and 49,802 vesting on March 3, 2027."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":49802,"derivative":{"underlying":"Ordinary Shares","underlying_shares":49800},"source":{"system":"sec-edgar","filing":"0001193125-26-093903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526093903/ownership.xml","form_type":"4"}},{"id":859906,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-05T21:03:19.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":141478,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":248756,"source":{"system":"sec-edgar","filing":"0001193125-26-093903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526093903/ownership.xml","form_type":"4"}},{"id":859905,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-05T21:03:19.000Z","date":"2026-03-03","kind":"exercise","planned":false,"acquired":true,"shares":49800,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":107278,"source":{"system":"sec-edgar","filing":"0001193125-26-093903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526093903/ownership.xml","form_type":"4"}},{"id":875690,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2026-03-02T21:01:38.000Z","date":"2026-02-26","kind":"sale","planned":true,"acquired":false,"shares":345810,"price":33.6448,"value":11634708.288,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.57 to $33.86, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":57478,"source":{"system":"sec-edgar","filing":"0001193125-26-085343","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526085343/ownership.xml","form_type":"4"}},{"id":928301,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2026-01-29T21:07:39.000Z","date":"2026-01-27","kind":"grant","planned":false,"acquired":true,"shares":141478,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":141478,"derivative":{"underlying":"Ordinary Shares","underlying_shares":141478},"source":{"system":"sec-edgar","filing":"0001193125-26-029337","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000119312526029337/ownership.xml","form_type":"4"}},{"id":1110514,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-06-16T20:03:30.000Z","date":"2025-06-12","kind":"sale","planned":true,"acquired":false,"shares":55775,"price":17.0769,"value":952464.0975,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.055 to $17.12, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":403288,"source":{"system":"sec-edgar","filing":"0000950170-25-086697","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025086697/ownership.xml","form_type":"4"}},{"id":1218516,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-07T21:19:21.000Z","date":"2025-03-05","kind":"grant","planned":false,"acquired":true,"shares":79664,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were granted on March 5, 2025, with 19,916 vesting on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were granted on March 5, 2025, with 19,916 vesting on each of March 5, 2026, March 5, 2027, March 5, 2028 and March 5, 2029."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":79664,"derivative":{"underlying":"Ordinary Shares","underlying_shares":79664},"source":{"system":"sec-edgar","filing":"0000950170-25-035528","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025035528/ownership.xml","form_type":"4"}},{"id":1218515,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-07T21:19:21.000Z","date":"2025-03-05","kind":"exercise","planned":false,"acquired":false,"shares":21390,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022, March 5, 2023, March 5, 2024, and 21,390 vested on March 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022, March 5, 2023, March 5, 2024, and 21,390 vested on March 5, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":21390},"source":{"system":"sec-edgar","filing":"0000950170-25-035528","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025035528/ownership.xml","form_type":"4"}},{"id":1218514,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-07T21:19:21.000Z","date":"2025-03-05","kind":"exercise","planned":false,"acquired":true,"shares":21390,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":459063,"source":{"system":"sec-edgar","filing":"0000950170-25-035528","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025035528/ownership.xml","form_type":"4"}},{"id":1220821,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-06T21:13:57.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":false,"shares":183169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":183169},"source":{"system":"sec-edgar","filing":"0000950170-25-034651","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034651/ownership.xml","form_type":"4"}},{"id":1220820,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-06T21:13:57.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":false,"shares":23251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were granted on March 4, 2024, with 23,251 vested on March 4, 2025, 23,251 vesting on each of March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were granted on March 4, 2024, with 23,251 vested on March 4, 2025, 23,251 vesting on each of March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":69754,"derivative":{"underlying":"Ordinary Shares","underlying_shares":23251},"source":{"system":"sec-edgar","filing":"0000950170-25-034651","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034651/ownership.xml","form_type":"4"}},{"id":1220819,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-06T21:13:57.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":false,"shares":33512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":33512,"derivative":{"underlying":"Ordinary Shares","underlying_shares":33512},"source":{"system":"sec-edgar","filing":"0000950170-25-034651","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034651/ownership.xml","form_type":"4"}},{"id":1220818,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-06T21:13:57.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":true,"shares":183169,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":437673,"source":{"system":"sec-edgar","filing":"0000950170-25-034651","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034651/ownership.xml","form_type":"4"}},{"id":1220817,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-06T21:13:57.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":true,"shares":23251,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":254504,"source":{"system":"sec-edgar","filing":"0000950170-25-034651","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034651/ownership.xml","form_type":"4"}},{"id":1220816,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-06T21:13:57.000Z","date":"2025-03-04","kind":"exercise","planned":false,"acquired":true,"shares":33512,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":231253,"source":{"system":"sec-edgar","filing":"0000950170-25-034651","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025034651/ownership.xml","form_type":"4"}},{"id":1233034,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2025-03-04T21:02:49.000Z","date":"2025-03-03","kind":"exercise","planned":true,"acquired":false,"shares":49800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024 and March 3,  2025, 49,800 vesting on March 3, 2026, and 49,802 vesting on March 3, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted share units were granted on March 3, 2023, with 49,800 vested on each of March 3, 2024 and March 3,  2025, 49,800 vesting on March 3, 2026, and 49,802 vesting on March 3, 2027."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":99602,"derivative":{"underlying":"Ordinary Shares","underlying_shares":49800},"source":{"system":"sec-edgar","filing":"0000950170-25-031946","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025031946/ownership.xml","form_type":"4"}},{"id":1233033,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-04T21:02:49.000Z","date":"2025-03-03","kind":"exercise","planned":true,"acquired":true,"shares":49800,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":197741,"source":{"system":"sec-edgar","filing":"0000950170-25-031946","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025031946/ownership.xml","form_type":"4"}},{"id":1233032,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2025-03-04T21:02:49.000Z","date":"2025-02-28","kind":"sale","planned":true,"acquired":false,"shares":55750,"price":16.2056,"value":903462.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 29, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.16 to $16.23, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":147941,"source":{"system":"sec-edgar","filing":"0000950170-25-031946","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025031946/ownership.xml","form_type":"4"}},{"id":1291304,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2025-01-30T21:01:48.000Z","date":"2025-01-28","kind":"grant","planned":false,"acquired":true,"shares":183169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":183169,"derivative":{"underlying":"Ordinary Shares","underlying_shares":183169},"source":{"system":"sec-edgar","filing":"0000950170-25-011059","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017025011059/ownership.xml","form_type":"4"}},{"id":1590220,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2024-03-07T21:27:55.000Z","date":"2024-03-05","kind":"exercise","planned":true,"acquired":false,"shares":52320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":52320},"source":{"system":"sec-edgar","filing":"0000950170-24-028015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024028015/ownership.xml","form_type":"4"}},{"id":1590219,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2024-03-07T21:27:55.000Z","date":"2024-03-05","kind":"exercise","planned":true,"acquired":false,"shares":21387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, and March 5, 2024, and 21,390 vesting on March 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, and March 5, 2024, and 21,390 vesting on March 5, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":21390,"derivative":{"underlying":"Ordinary Shares","underlying_shares":21387},"source":{"system":"sec-edgar","filing":"0000950170-24-028015","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024028015/ownership.xml","form_type":"4"}},{"id":1590218,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-07T21:27:55.000Z","date":"2024-03-06","kind":"sale","planned":true,"acquired":false,"shares":77550,"price":13.5154,"value":1048119.27,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F3","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":203691,"source":{"system":"sec-edgar","filing":"0000950170-24-028015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024028015/ownership.xml","form_type":"4"}},{"id":1590217,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-07T21:27:55.000Z","date":"2024-03-05","kind":"exercise","planned":true,"acquired":true,"shares":21387,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":281241,"source":{"system":"sec-edgar","filing":"0000950170-24-028015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024028015/ownership.xml","form_type":"4"}},{"id":1590216,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-07T21:27:55.000Z","date":"2024-03-05","kind":"exercise","planned":true,"acquired":true,"shares":52320,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":259854,"source":{"system":"sec-edgar","filing":"0000950170-24-028015","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024028015/ownership.xml","form_type":"4"}},{"id":1600181,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2024-03-05T21:08:27.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":93005,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted share units were granted on March 4, 2024, with 23,251 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted share units were granted on March 4, 2024, with 23,251 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":93005,"derivative":{"underlying":"Ordinary Shares","underlying_shares":93005},"source":{"system":"sec-edgar","filing":"0000950170-24-025888","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024025888/ownership.xml","form_type":"4"}},{"id":1600180,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2024-03-05T21:08:27.000Z","date":"2024-03-04","kind":"exercise","planned":false,"acquired":false,"shares":33512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":207534,"derivative":{"underlying":"Ordinary Shares","underlying_shares":33512},"source":{"system":"sec-edgar","filing":"0000950170-24-025888","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024025888/ownership.xml","form_type":"4"}},{"id":1600179,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2024-03-05T21:08:27.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":false,"shares":49800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":174022,"derivative":{"underlying":"Ordinary Shares","underlying_shares":49800},"source":{"system":"sec-edgar","filing":"0000950170-24-025888","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024025888/ownership.xml","form_type":"4"}},{"id":1600178,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-05T21:08:27.000Z","date":"2024-03-04","kind":"exercise","planned":false,"acquired":true,"shares":33512,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":207534,"source":{"system":"sec-edgar","filing":"0000950170-24-025888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024025888/ownership.xml","form_type":"4"}},{"id":1600177,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-05T21:08:27.000Z","date":"2024-03-03","kind":"exercise","planned":false,"acquired":true,"shares":49800,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":174022,"source":{"system":"sec-edgar","filing":"0000950170-24-025888","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024025888/ownership.xml","form_type":"4"}},{"id":1608757,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2024-03-01T11:54:56.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":false,"shares":18430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on February 28, 2020 with 18,430 vesting on each of February 28, 2021, February 28, 2022, February 28,\n2023 and February 28, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on February 28, 2020 with 18,430 vesting on each of February 28, 2021, February 28, 2022, February 28,\n2023 and February 28, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18430},"source":{"system":"sec-edgar","filing":"0000950170-24-023530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024023530/ownership.xml","form_type":"4"}},{"id":1608756,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2024-03-01T11:54:56.000Z","date":"2024-02-28","kind":"exercise","planned":false,"acquired":true,"shares":18430,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":124222,"source":{"system":"sec-edgar","filing":"0000950170-24-023530","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024023530/ownership.xml","form_type":"4"}},{"id":1641961,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2024-02-15T12:37:12.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":6630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022, and February 13, 2023, and 6,630 vesting on February 13, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022, and February 13, 2023, and 6,630 vesting on February 13, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6630},"source":{"system":"sec-edgar","filing":"0000950170-24-015601","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024015601/ownership.xml","form_type":"4"}},{"id":1641960,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2024-02-15T12:37:12.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":6630,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":105792,"source":{"system":"sec-edgar","filing":"0000950170-24-015601","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024015601/ownership.xml","form_type":"4"}},{"id":1664409,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2024-02-01T12:26:17.000Z","date":"2024-01-30","kind":"grant","planned":false,"acquired":true,"shares":52320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 5, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":52320,"derivative":{"underlying":"Ordinary Shares","underlying_shares":52320},"source":{"system":"sec-edgar","filing":"0000950170-24-009614","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000095017024009614/ownership.xml","form_type":"4"}},{"id":1812488,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2023-08-09T20:02:12.000Z","date":"2023-08-07","kind":"sale","planned":false,"acquired":false,"shares":35125,"price":9.7335,"value":341889.1875,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.71 to $9.77, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":99162,"source":{"system":"sec-edgar","filing":"0001209191-23-045156","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123045156/doc4.xml","form_type":"4"}},{"id":1967237,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2023-03-07T21:10:42.000Z","date":"2023-03-05","kind":"exercise","acquired":false,"shares":21387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022 and March 5, 2023, 21,387 vesting on March 5, 2024, and 21,390 vesting on March 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Restricted share units were granted on March 5, 2021, with 21,387 vested on each of March 5, 2022 and March 5, 2023, 21,387 vesting on March 5, 2024, and 21,390 vesting on March 5, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":42777,"derivative":{"underlying":"Ordinary Shares","underlying_shares":21387},"source":{"system":"sec-edgar","filing":"0001209191-23-016712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123016712/doc4.xml","form_type":"4"}},{"id":1967236,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2023-03-07T21:10:42.000Z","date":"2023-03-04","kind":"exercise","acquired":false,"shares":33512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023, and 33,512 vesting on each of March 4, 2024, March 4, 2025 and March 4, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":100536,"derivative":{"underlying":"Ordinary Shares","underlying_shares":33512},"source":{"system":"sec-edgar","filing":"0001209191-23-016712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123016712/doc4.xml","form_type":"4"}},{"id":1967235,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2023-03-07T21:10:42.000Z","date":"2023-03-03","kind":"grant","acquired":true,"shares":199202,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on March 3, 2023, with 49,800 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 49,802 vesting on March 3, 2027."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":199202,"derivative":{"underlying":"Ordinary Shares","underlying_shares":199202},"source":{"system":"sec-edgar","filing":"0001209191-23-016712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123016712/doc4.xml","form_type":"4"}},{"id":1967234,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-07T21:10:42.000Z","date":"2023-03-05","kind":"exercise","acquired":true,"shares":21387,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":134287,"source":{"system":"sec-edgar","filing":"0001209191-23-016712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123016712/doc4.xml","form_type":"4"}},{"id":1967233,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-07T21:10:42.000Z","date":"2023-03-04","kind":"exercise","acquired":true,"shares":33512,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":112900,"source":{"system":"sec-edgar","filing":"0001209191-23-016712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123016712/doc4.xml","form_type":"4"}},{"id":1981783,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2023-03-02T12:36:02.000Z","date":"2023-02-28","kind":"exercise","acquired":false,"shares":44953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were granted on February 7, 2023 pursuant to the satisfaction of performance criteria and vested on February 28, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":44953},"source":{"system":"sec-edgar","filing":"0001209191-23-014439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123014439/doc4.xml","form_type":"4"}},{"id":1981782,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2023-03-02T12:36:02.000Z","date":"2023-02-28","kind":"exercise","acquired":false,"shares":18430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on February 28, 2020 with 18,430 vested on each of February 28, 2021, February 28, 2022, February 28, 2023 and 18,430 vesting on February 28, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on February 28, 2020 with 18,430 vested on each of February 28, 2021, February 28, 2022, February 28, 2023 and 18,430 vesting on February 28, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18430,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18430},"source":{"system":"sec-edgar","filing":"0001209191-23-014439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123014439/doc4.xml","form_type":"4"}},{"id":1981781,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-02T12:36:02.000Z","date":"2023-02-28","kind":"exercise","acquired":true,"shares":44953,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":79388,"source":{"system":"sec-edgar","filing":"0001209191-23-014439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123014439/doc4.xml","form_type":"4"}},{"id":1981780,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2023-03-02T12:36:02.000Z","date":"2023-02-28","kind":"exercise","acquired":true,"shares":18430,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":34435,"source":{"system":"sec-edgar","filing":"0001209191-23-014439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123014439/doc4.xml","form_type":"4"}},{"id":2014419,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2023-02-15T12:20:37.000Z","date":"2023-02-13","kind":"exercise","acquired":false,"shares":6629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022, and February 13, 2023, and 6,630 vesting on February 13, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022, and February 13, 2023, and 6,630 vesting on February 13, 2024."}],"balance_after":6630,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6629},"source":{"system":"sec-edgar","filing":"0001209191-23-009613","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123009613/doc4.xml","form_type":"4"}},{"id":2014418,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2023-02-15T12:20:37.000Z","date":"2023-02-13","kind":"exercise","acquired":true,"shares":6629,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":16005,"source":{"system":"sec-edgar","filing":"0001209191-23-009613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123009613/doc4.xml","form_type":"4"}},{"id":2025601,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2023-02-09T12:04:08.000Z","date":"2023-02-07","kind":"grant","acquired":true,"shares":44953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on February 28, 2023."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":44953,"derivative":{"underlying":"Ordinary Shares","underlying_shares":44953},"source":{"system":"sec-edgar","filing":"0001209191-23-007952","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919123007952/doc4.xml","form_type":"4"}},{"id":2175508,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2022-08-24T11:50:34.000Z","date":"2022-08-22","kind":"sale","acquired":false,"shares":55500,"price":10.0666,"value":558696.3,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.000 to $10.175, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":9376,"source":{"system":"sec-edgar","filing":"0001209191-22-047291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122047291/doc4.xml","form_type":"4"}},{"id":2345924,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2022-03-08T21:10:16.000Z","date":"2022-03-05","kind":"exercise","acquired":false,"shares":21387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 21,390\nvesting on March 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 21,390\nvesting on March 5, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":64164,"derivative":{"underlying":"Ordinary Shares","underlying_shares":21387},"source":{"system":"sec-edgar","filing":"0001209191-22-017054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017054/doc4.xml","form_type":"4"}},{"id":2345923,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2022-03-08T21:10:16.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":134048,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on March 4, 2022, with 33,512 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":134048,"derivative":{"underlying":"Ordinary Shares","underlying_shares":134048},"source":{"system":"sec-edgar","filing":"0001209191-22-017054","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017054/doc4.xml","form_type":"4"}},{"id":2345922,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-08T21:10:16.000Z","date":"2022-03-05","kind":"exercise","acquired":true,"shares":21387,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":64876,"source":{"system":"sec-edgar","filing":"0001209191-22-017054","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122017054/doc4.xml","form_type":"4"}},{"id":2363040,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2022-03-02T12:49:31.000Z","date":"2022-02-28","kind":"exercise","acquired":false,"shares":18430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on February 28, 2020, with 18,430 having vested on each of February 28, 2021 and February 28, 2022, and\n18,430 vesting on each of February 28, 2023 and February 28, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on February 28, 2020, with 18,430 having vested on each of February 28, 2021 and February 28, 2022, and\n18,430 vesting on each of February 28, 2023 and February 28, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":36860,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18430},"source":{"system":"sec-edgar","filing":"0001209191-22-014471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122014471/doc4.xml","form_type":"4"}},{"id":2363039,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2022-03-02T12:49:31.000Z","date":"2022-02-28","kind":"exercise","acquired":true,"shares":18430,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":43489,"source":{"system":"sec-edgar","filing":"0001209191-22-014471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122014471/doc4.xml","form_type":"4"}},{"id":2395756,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2022-02-15T12:28:37.000Z","date":"2022-02-13","kind":"exercise","acquired":false,"shares":6629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022 and February 13, 2023 and 6,630 vesting on February 13, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022 and February 13, 2023 and 6,630 vesting on February 13, 2024."}],"balance_after":13259,"derivative":{"underlying":"Ordinary Shares","underlying_shares":6629},"source":{"system":"sec-edgar","filing":"0001209191-22-009630","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122009630/doc4.xml","form_type":"4"}},{"id":2395755,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-15T12:28:37.000Z","date":"2022-02-13","kind":"exercise","acquired":true,"shares":6629,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources\nand Compensation Committee, the cash value of one ordinary share."}],"balance_after":25059,"source":{"system":"sec-edgar","filing":"0001209191-22-009630","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919122009630/doc4.xml","form_type":"4"}},{"id":2804323,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-08T21:07:49.000Z","date":"2021-03-05","kind":"grant","acquired":true,"shares":85551,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 21,390 vesting on March 5, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, March 5, 2024 and 21,390 vesting on March 5, 2025."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":85551,"derivative":{"underlying":"Ordinary Shares","underlying_shares":85551},"source":{"system":"sec-edgar","filing":"0001209191-21-018522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121018522/doc4.xml","form_type":"4"}},{"id":2823335,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2021-03-02T21:06:25.000Z","date":"2021-02-28","kind":"exercise","acquired":false,"shares":18430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted share units were granted on February 28, 2020 with 18,430 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted share units were granted on February 28, 2020 with 18,430 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":55290,"derivative":{"underlying":"Ordinary Shares","underlying_shares":18430},"source":{"system":"sec-edgar","filing":"0001209191-21-015845","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121015845/doc4.xml","form_type":"4"}},{"id":2823334,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-03-02T21:06:25.000Z","date":"2021-02-28","kind":"exercise","acquired":true,"shares":18430,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."}],"balance_after":18430,"source":{"system":"sec-edgar","filing":"0001209191-21-015845","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919121015845/doc4.xml","form_type":"4"}},{"id":3235427,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2020-03-03T12:14:07.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":73720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted share units were granted on February 28, 2020 with 18,430 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted share units were granted on February 28, 2020 with 18,430 vesting on each of February 28, 2021, February 28, 2022, February 28, 2023 and February 28, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":73720,"derivative":{"underlying":"Ordinary Shares","underlying_shares":73720},"source":{"system":"sec-edgar","filing":"0001209191-20-014851","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120014851/doc4.xml","form_type":"4"}},{"id":3268519,"issuer":{"id":3063,"kind":"organization","name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","symbol":"TEVA"},"owners":[{"id":37892,"kind":"person","name":"Kalif Eliyahu Sharon","position":1,"cik":"0001798443","reported_name":"Kalif Eliyahu Sharon","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Financial Officer"}}],"security":"Restricted Share Units","published_at":"2020-02-18T12:21:56.000Z","date":"2020-02-13","kind":"grant","acquired":true,"shares":19888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022 and February 13, 2023 and 6,630 vesting on February 13, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022 and February 13, 2023 and 6,630 vesting on February 13, 2024."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F3","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19888,"derivative":{"underlying":"Ordinary Shares","underlying_shares":19888},"source":{"system":"sec-edgar","filing":"0001209191-20-009877","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/818686/000120919120009877/doc4.xml","form_type":"4"}}]}